Salvage therapy with single-agent paclitaxel by three-hour infusion in metastatic breast cancer: An experience in Taipei Veterans General Hospital

Cheng Jeng Tai, Wei Shu Wang, Jin Hwang Liu, Chueh Chuan Yen, Frank Sheng Fan, Tzeon Jye Chiou, Po Min Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Paclitaxel is an active agent in the treatment of breast, ovarian, lung and head and neck cancers. In previous phase I and II trials, it exerted novel cytotoxic effect on several malignancies. Various doses and regimens of paclitaxel have been assessed in metastatic breast cancer, with responses between 20 and 62%. However, combination therapy with other anti-cancer drugs leads to a high incidence of side effects. Our aim was to evaluate the efficacy of paclitaxel given by 3 h infusion as salvage chemotherapy for patients with metastatic breast cancer. Methods: Between May 1999 and April 2000, 14 women with metastatic breast cancer were enrolled in this study and all the patients had to have measurable lesions. The median age of the patients was 48.7 years (range 39-56 years). All of them were definitely evidenced as having metastatic breast cancer and received complete courses of anthracycline-containing agents before applying paclitaxel. The protocol was single-agent paclitaxel (Anzatax, Faulding, Australia) at a moderate dosage of 175 mg/m2 by 3 h intravenous infusion every 3 weeks. Results: A total of 75 cycles were administered to these 14 patients with a median of four delivered cycles (range 3-14) and the response rate was 28.6% (95% CI: 21-40%), including four partial remission, three stable disease and seven progressive disease. The median time to progression was 3 (range 3-7) months. Hematological toxicities were minimal with no evidence of severe (grade 3 or 4) leukopenia and thrombocytopenia. Hepatic toxicities were observed in 12 cycles with five in grade 3. Conclusions: Our study indicates that utilizing single-agent paclitaxel exerts moderate activity on anthracycline-refractory metastatic breast cancer patients without excessive toxicities.

Original languageEnglish
Pages (from-to)477-481
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume31
Issue number10
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Veterans Hospitals
Salvage Therapy
Paclitaxel
General Hospitals
Breast Neoplasms
Anthracyclines
Leukopenia
Head and Neck Neoplasms
Intravenous Infusions
Lung Neoplasms
Neoplasms
Breast
Drug Therapy
Liver
Incidence
Therapeutics
Pharmaceutical Preparations

Keywords

  • Anzatax
  • Chemotherapy
  • Metastatic breast cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology

Cite this

Salvage therapy with single-agent paclitaxel by three-hour infusion in metastatic breast cancer : An experience in Taipei Veterans General Hospital. / Tai, Cheng Jeng; Wang, Wei Shu; Liu, Jin Hwang; Yen, Chueh Chuan; Fan, Frank Sheng; Chiou, Tzeon Jye; Chen, Po Min.

In: Japanese Journal of Clinical Oncology, Vol. 31, No. 10, 2001, p. 477-481.

Research output: Contribution to journalArticle

Tai, Cheng Jeng ; Wang, Wei Shu ; Liu, Jin Hwang ; Yen, Chueh Chuan ; Fan, Frank Sheng ; Chiou, Tzeon Jye ; Chen, Po Min. / Salvage therapy with single-agent paclitaxel by three-hour infusion in metastatic breast cancer : An experience in Taipei Veterans General Hospital. In: Japanese Journal of Clinical Oncology. 2001 ; Vol. 31, No. 10. pp. 477-481.
@article{1499b3f30a3c47f79df5078934856005,
title = "Salvage therapy with single-agent paclitaxel by three-hour infusion in metastatic breast cancer: An experience in Taipei Veterans General Hospital",
abstract = "Background: Paclitaxel is an active agent in the treatment of breast, ovarian, lung and head and neck cancers. In previous phase I and II trials, it exerted novel cytotoxic effect on several malignancies. Various doses and regimens of paclitaxel have been assessed in metastatic breast cancer, with responses between 20 and 62{\%}. However, combination therapy with other anti-cancer drugs leads to a high incidence of side effects. Our aim was to evaluate the efficacy of paclitaxel given by 3 h infusion as salvage chemotherapy for patients with metastatic breast cancer. Methods: Between May 1999 and April 2000, 14 women with metastatic breast cancer were enrolled in this study and all the patients had to have measurable lesions. The median age of the patients was 48.7 years (range 39-56 years). All of them were definitely evidenced as having metastatic breast cancer and received complete courses of anthracycline-containing agents before applying paclitaxel. The protocol was single-agent paclitaxel (Anzatax, Faulding, Australia) at a moderate dosage of 175 mg/m2 by 3 h intravenous infusion every 3 weeks. Results: A total of 75 cycles were administered to these 14 patients with a median of four delivered cycles (range 3-14) and the response rate was 28.6{\%} (95{\%} CI: 21-40{\%}), including four partial remission, three stable disease and seven progressive disease. The median time to progression was 3 (range 3-7) months. Hematological toxicities were minimal with no evidence of severe (grade 3 or 4) leukopenia and thrombocytopenia. Hepatic toxicities were observed in 12 cycles with five in grade 3. Conclusions: Our study indicates that utilizing single-agent paclitaxel exerts moderate activity on anthracycline-refractory metastatic breast cancer patients without excessive toxicities.",
keywords = "Anzatax, Chemotherapy, Metastatic breast cancer, Paclitaxel",
author = "Tai, {Cheng Jeng} and Wang, {Wei Shu} and Liu, {Jin Hwang} and Yen, {Chueh Chuan} and Fan, {Frank Sheng} and Chiou, {Tzeon Jye} and Chen, {Po Min}",
year = "2001",
language = "English",
volume = "31",
pages = "477--481",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Salvage therapy with single-agent paclitaxel by three-hour infusion in metastatic breast cancer

T2 - An experience in Taipei Veterans General Hospital

AU - Tai, Cheng Jeng

AU - Wang, Wei Shu

AU - Liu, Jin Hwang

AU - Yen, Chueh Chuan

AU - Fan, Frank Sheng

AU - Chiou, Tzeon Jye

AU - Chen, Po Min

PY - 2001

Y1 - 2001

N2 - Background: Paclitaxel is an active agent in the treatment of breast, ovarian, lung and head and neck cancers. In previous phase I and II trials, it exerted novel cytotoxic effect on several malignancies. Various doses and regimens of paclitaxel have been assessed in metastatic breast cancer, with responses between 20 and 62%. However, combination therapy with other anti-cancer drugs leads to a high incidence of side effects. Our aim was to evaluate the efficacy of paclitaxel given by 3 h infusion as salvage chemotherapy for patients with metastatic breast cancer. Methods: Between May 1999 and April 2000, 14 women with metastatic breast cancer were enrolled in this study and all the patients had to have measurable lesions. The median age of the patients was 48.7 years (range 39-56 years). All of them were definitely evidenced as having metastatic breast cancer and received complete courses of anthracycline-containing agents before applying paclitaxel. The protocol was single-agent paclitaxel (Anzatax, Faulding, Australia) at a moderate dosage of 175 mg/m2 by 3 h intravenous infusion every 3 weeks. Results: A total of 75 cycles were administered to these 14 patients with a median of four delivered cycles (range 3-14) and the response rate was 28.6% (95% CI: 21-40%), including four partial remission, three stable disease and seven progressive disease. The median time to progression was 3 (range 3-7) months. Hematological toxicities were minimal with no evidence of severe (grade 3 or 4) leukopenia and thrombocytopenia. Hepatic toxicities were observed in 12 cycles with five in grade 3. Conclusions: Our study indicates that utilizing single-agent paclitaxel exerts moderate activity on anthracycline-refractory metastatic breast cancer patients without excessive toxicities.

AB - Background: Paclitaxel is an active agent in the treatment of breast, ovarian, lung and head and neck cancers. In previous phase I and II trials, it exerted novel cytotoxic effect on several malignancies. Various doses and regimens of paclitaxel have been assessed in metastatic breast cancer, with responses between 20 and 62%. However, combination therapy with other anti-cancer drugs leads to a high incidence of side effects. Our aim was to evaluate the efficacy of paclitaxel given by 3 h infusion as salvage chemotherapy for patients with metastatic breast cancer. Methods: Between May 1999 and April 2000, 14 women with metastatic breast cancer were enrolled in this study and all the patients had to have measurable lesions. The median age of the patients was 48.7 years (range 39-56 years). All of them were definitely evidenced as having metastatic breast cancer and received complete courses of anthracycline-containing agents before applying paclitaxel. The protocol was single-agent paclitaxel (Anzatax, Faulding, Australia) at a moderate dosage of 175 mg/m2 by 3 h intravenous infusion every 3 weeks. Results: A total of 75 cycles were administered to these 14 patients with a median of four delivered cycles (range 3-14) and the response rate was 28.6% (95% CI: 21-40%), including four partial remission, three stable disease and seven progressive disease. The median time to progression was 3 (range 3-7) months. Hematological toxicities were minimal with no evidence of severe (grade 3 or 4) leukopenia and thrombocytopenia. Hepatic toxicities were observed in 12 cycles with five in grade 3. Conclusions: Our study indicates that utilizing single-agent paclitaxel exerts moderate activity on anthracycline-refractory metastatic breast cancer patients without excessive toxicities.

KW - Anzatax

KW - Chemotherapy

KW - Metastatic breast cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0034754470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034754470&partnerID=8YFLogxK

M3 - Article

C2 - 11696616

AN - SCOPUS:0034754470

VL - 31

SP - 477

EP - 481

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -